Prime medicine inc PRME.US 總覽分析
PRME 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
PRME 近期報酬表現
-3.45%
Prime medicine inc
3.56%
同產業平均
1.47%
S&P500
與 PRME 同產業的標的表現
- NTLA Intellia therapeutics inc價值 4 分趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
PRME 公司資訊
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson's Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.